Standard Chemoradiation and Conventional Brachytherapy for Locally Advanced Cervical Cancer: Is It Still Applicable in the Era of Magnetic Resonance-Based Brachytherapy? (Record no. 83281)

000 -LEADER
fixed length control field 02966nab a22003377a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 180820b2018 xxu||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Mittal P
245 ## - TITLE STATEMENT
Title Standard Chemoradiation and Conventional Brachytherapy for Locally Advanced Cervical Cancer: Is It Still Applicable in the Era of Magnetic Resonance-Based Brachytherapy?
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc 2018
300 ## - PHYSICAL DESCRIPTION
Extent
500 ## - GENERAL NOTE
General note Address for correspondence: supriyasastri@gmail.com.
520 ## - SUMMARY, ETC.
Summary, etc Purpose
Recent guidelines recommend magnetic resonance imaging–based brachytherapy (MRBT) for locally advanced cervical cancer. However, its implementation is challenging within the developing world. This article reports the outcomes of patients with locally advanced cervical cancer treated with chemoradiation and point A–based brachytherapy (BT) using x-ray– or computed tomography–based planning.

Methods
Patients treated between January 2014 and December 2015 were included. Patients underwent x-ray– or computed tomography–based BT planning with an aim to deliver equivalent doses in 2 Gy (EQD2) > 84 Gy10 to point A while minimizing maximum dose received by rectum or bladder to a point or 2 cc volume to < 75 Gy EQD2 and < 90 Gy EQD2, respectively. The impact of known prognostic factors was evaluated.

Results
A total of 339 patients were evaluated. Median age was 52 (32 to 81) years; 52% of patients had stage IB2 to IIB and 48% had stage III to IVA disease. There was 85% compliance with chemoradiation, and 87% of patients received four or more cycles. Median point A dose was 84 (64.8 to 89.7) Gy. The median rectal and bladder doses were 73.5 (69.6 to 78.4) Gy3 and 83 (73.2 to 90.0) Gy3, respectively. At a median follow-up of 28 (4 to 45) months, the 3-year local, disease-free, and overall survival for stage IB to IIB disease was 94.1%, 83.3%, and 82.7%, respectively. The corresponding rates for stage III to IVA were 85.1%, 60.7%, and 69.6%. Grade III to IV proctitis and cystitis were observed in 4.7% and 0% of patients, respectively.

Conclusion
This audit demonstrates good 3-year outcomes that are comparable to published MRBT series. Conventional BT with selective use of interstitial needles and MRBT should continue as standard procedures until level-I evidence for MRBT becomes available.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Cervical cancer
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element MRBT
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Magnetic resonance imaging-based brachytherapy
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Developing world
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Chopra S
Relator term Corresponding author
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Pant S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Mahantshetty U
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Engineer R
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Ghosh J
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gupta S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Ghadi Y
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Menachery S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Swamidas J
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gurram L
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Shrivastava SK
773 ## - HOST ITEM ENTRY
Main entry heading Journal of Global Oncology
Place, publisher, and date of publication Alexandria, VA : American Society of Clinical Oncology, 2018
Relationship information Vol. 4):1-9.
International Standard Serial Number Journal of global oncology.
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
Dept Radiation Oncology
Corporate name TMC
PMID 30085892
Article Type Journal Article
Country type International
Added Entry TMH
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Item type Articles
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Permanent location Current location Date acquired Barcode Date last seen Koha item type
          Tata Memorial Hospital Tata Memorial Hospital 2018-08-20 AR19127 2018-08-20 Articles

Powered by Koha